Loxo Oncology, Inc. (LOXO)

Oncology Corporate Profile

Stock Performance

23.5200
-0.9200

HQ Location

1 Landmark Square, Suite 1122
Stamford, CT 6901

Company Description

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, MD. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for clinical success in genetically defined patient populations.

Website: http://www.loxooncology.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Loxo-101tropomyocin receptor kinase A (TrkA) inhibitorVarious cancer typesII
Loxo-101tropomyocin receptor kinase A (TrkA) inhibitorSarcomaI

View additional information on product candidates here »

Source: http://www.loxooncology.com

Recent News Headlines

5/26/2017 06:18 am

5/26/2017 06:18 am

5/26/2017 06:18 am

5/26/2017 06:18 am

5/22/2017 06:18 am

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/16/2017 06:18 am

5/16/2017 06:18 am

5/16/2017 06:18 am

5/16/2017 06:18 am

5/12/2017 12:18 am

5/12/2017 12:18 am

5/12/2017 12:18 am

5/12/2017 12:18 am

5/9/2017 12:18 am

5/9/2017 12:18 am

5/2/2017 12:18 am

Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017

3/31/2017 08:03 pm

[GlobeNewswire] - STAMFORD, Conn., March 31, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...